Literature DB >> 12565863

Effect of cisplatin treatment on speckled distribution of a serine/arginine-rich nuclear protein CROP/Luc7A.

Hiroshi Umehara1, Yoichi Nishii, Masaki Morishima, Yoshiyuki Kakehi, Noriyuki Kioka, Teruo Amachi, Jun Koizumi, Masatoshi Hagiwara, Kazumitsu Ueda.   

Abstract

The C-half of cisplatin resistance-associated overexpressed protein (CROP), an SR-related protein, comprises domains rich in arginine and glutamate residues (RE domain), and is rich in arginine and serine residues (RS domain). We analyzed the role of the individual domains of CROP in cellular localization, subnuclear localization, and protein-protein interaction. CROP fused with green fluorescent protein, GFP-CROP, localized exclusively to the nucleus and showed a speckled intranuclear distribution. The yeast two-hybrid system revealed that CROP interacted with SF2/ASF, an SR protein involved in RNA splicing, as well as CROP itself. The RE and RS domains were necessary for both the intranuclear speckled distribution and the protein-protein interaction. CROP was phosphorylated by mSRPK1, mSRPK2, and Clk1 in vitro, and when cells were treated with cisplatin the subnuclear distribution of GFP-CROP was changed. These results suggest that cisplatin affects RNA splicing by changing the subnuclear distribution of SR proteins including CROP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12565863     DOI: 10.1016/s0006-291x(02)03017-6

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCbetaII messenger ribonucleic acid.

Authors:  Kun Jiang; Niketa A Patel; James E Watson; Hercules Apostolatos; Eden Kleiman; Olivia Hanson; Masatoshi Hagiwara; Denise R Cooper
Journal:  Endocrinology       Date:  2008-12-30       Impact factor: 4.736

2.  Synthesis and biologic properties of hydrophilic sapphyrins, a new class of tumor-selective inhibitors of gene expression.

Authors:  Zhong Wang; Philip S Lecane; Patricia Thiemann; Qing Fan; Cecilia Cortez; Xuan Ma; Danielle Tonev; Dale Miles; Louie Naumovski; Richard A Miller; Darren Magda; Dong-Gyu Cho; Jonathan L Sessler; Brian L Pike; Samantha M Yeligar; Mazen W Karaman; Joseph G Hacia
Journal:  Mol Cancer       Date:  2007-01-19       Impact factor: 27.401

3.  XE7: a novel splicing factor that interacts with ASF/SF2 and ZNF265.

Authors:  A Helena Mangs; Helen J L Speirs; Christine Goy; David J Adams; M Andrea Markus; Brian J Morris
Journal:  Nucleic Acids Res       Date:  2006-09-18       Impact factor: 16.971

4.  Fish Myogenic Regulatory Protein LUC7L: Characterization and Expression Analysis in Korean Rose Bitterling (Rhodeus uyekii).

Authors:  Ju Lan Kim; Hee Jeong Kong; Hyung Soo Kim; Woo-Jin Kim; Dong-Gyun Kim; Bo-Hye Nam; Young-Ok Kim; Cheul Min An
Journal:  Dev Reprod       Date:  2014-12

5.  LUC7L3/CROP inhibits replication of hepatitis B virus via suppressing enhancer II/basal core promoter activity.

Authors:  Yuan Li; Masahiko Ito; Suofeng Sun; Takeshi Chida; Kenji Nakashima; Tetsuro Suzuki
Journal:  Sci Rep       Date:  2016-11-18       Impact factor: 4.379

6.  Tyramide signal amplification mass spectrometry (TSA-MS) ratio identifies nuclear speckle proteins.

Authors:  Joseph Dopie; Michael J Sweredoski; Annie Moradian; Andrew S Belmont
Journal:  J Cell Biol       Date:  2020-09-07       Impact factor: 10.539

7.  Whole blood transcriptome correlates with treatment response in nasopharyngeal carcinoma.

Authors:  Adel M Zaatar; Chun Ren Lim; Chin Wei Bong; Michelle Mei Lin Lee; Jian Jiek Ooi; David Suria; Rakesh Raman; Samuel Chao; Hengxuan Yang; Soon Bin Neoh; Choong-Chin Liew
Journal:  J Exp Clin Cancer Res       Date:  2012-09-17

8.  RRP1B is a metastasis modifier that regulates the expression of alternative mRNA isoforms through interactions with SRSF1.

Authors:  M Lee; A M Dworkin; D Gildea; N S Trivedi; G B Moorhead; N P S Crawford
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.